ArticleAutoimmune diseases2011
B-cell-activating factor and autoimmune myasthenia gravis.
Article in Autoimmune diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis.Frontiers in immunology · 2023Pooled it
- A Rare Case of Chronic Lymphocytic Leukemia Complicated by Myasthenia Gravis.Journal of community hospital internal medicine perspectives · 2025Article
- Treating myasthenia gravis beyond the eye clinic.Eye (London, England) · 2024Review
- Novel Immunotherapies for Myasthenia Gravis.ImmunoTargets and therapy · 2023Review
- Inflammation and autoimmune myasthenia gravis.Frontiers in immunology · 2023Review
- Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.Journal of clinical medicine · 2021Review
- Novel Treatments in Myasthenia Gravis.Frontiers in neurology · 2020Review
- The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (Mediators of inflammation · 2020Article
- Mucosa-associated lymphoid tissue lymphoma of the accessory parotid gland presenting as a simple cheek mass: A case report.Medicine · 2019Article
- Advances in autoimmune myasthenia gravis management.Expert review of neurotherapeutics · 2018Review
- Regulatory B Cells in Seropositive Myasthenia Gravis versus Healthy Controls.Frontiers in neurology · 2017Article
- Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Elevated serum levels of visfatin in patients with henoch-schönlein purpura.Annals of dermatology · 2014Article
- Myasthenia gravis: an update for the clinician.Clinical and experimental immunology · 2014Review
- New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.Journal of neuromuscular diseasesReview
- Immunogenicity of therapeutic proteins: influence of aggregation.Journal of immunotoxicologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BAFF is a potent B-cell survival factor, and it plays an essential role in B-cell homeostasis and B-cell function in the periphery. Both normal and autoreactive B cells are BAFF dependent; however, excess BAFF promotes the survival, growth, and maturation of autoreactive B cells. When overexpressed, BAFF protects B cells from apoptosis, thereby contributing to autoimmunity. Three independent studies have shown higher BAFF levels in the circulation of MG patients. BAFF may play an important role in the pathogenesis of MG. BAFF antagonists may well provide new treatment options for MG patients, particularly those patients with thymic lymphoid follicular hyperplasia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.